Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5414/CP203772 http://scihub22266oqcxt.onion/10.5414/CP203772 32729823!ä!32729823 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Clin+Pharmacol+Ther 2020 ; 58 (10): 568-574 Nephropedia Template TP {{tp|p=32729823|t=2020. Drug evaluation and pharmaceutical care in a critically ill COVID-19 patient |pdf=|usr=}}{{32729823}} gab.com Text Drug evaluation and pharmaceutical care in a critically ill COVID-19 patient JO: Int J Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32729823 #FOAvip BACKGROUND: Currently, the novel coronavirus pneumonia is rampaging around the world, 13.2 - 21.3% of patients with COVID-19 infection developed severe or critical illness. Treatment of these critically ill patients is becoming one of the major challenges we are facing. Frequently, more than 10 types of drugs are used simultaneously in the treatment of these critically ill patients, and the combination of many different drugs may easily lead to drug interactions and adverse reactions. Therefore, clinical pharmacist should participate in the optimization of drug treatment programs. MATERIALS AND METHODS: A case of a critically ill COVID-19 patient with respiratory failure and diabetes mellitus is used as an example of an analysis of the treatment plan, utilization of combined medications, and the delivery of pharmaceutical care. RESULTS: There were some drug use unreasonable phenomena, including the extended continuation of arbidol treatment, the use of broad-spectrum antibacterial drugs, the use of drugs with unproven anti-coronavirus effects. CONCLUSION: Clinical pharmacists should participate in the optimization of drug treatment programs and provide pharmaceutical care for critically ill COVID-19 patients; this can promote the rational use of drugs. Twit Text FOAVip Drug evaluation and pharmaceutical care in a critically ill COVID-19 patient ????Int J Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32729823 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32729823 #FOAvip English Wikipedia <ref>{{Cite pmid|32729823}}</ref> Drug evaluation and pharmaceutical care in a critically ill COVID-19 patient #MMPMID32729823 Li X; Li Y; Guo S; Liu W Int J Clin Pharmacol Ther 2020[Oct]; 58 (10): 568-574 PMID32729823show ga BACKGROUND: Currently, the novel coronavirus pneumonia is rampaging around the world, 13.2 - 21.3% of patients with COVID-19 infection developed severe or critical illness. Treatment of these critically ill patients is becoming one of the major challenges we are facing. Frequently, more than 10 types of drugs are used simultaneously in the treatment of these critically ill patients, and the combination of many different drugs may easily lead to drug interactions and adverse reactions. Therefore, clinical pharmacist should participate in the optimization of drug treatment programs. MATERIALS AND METHODS: A case of a critically ill COVID-19 patient with respiratory failure and diabetes mellitus is used as an example of an analysis of the treatment plan, utilization of combined medications, and the delivery of pharmaceutical care. RESULTS: There were some drug use unreasonable phenomena, including the extended continuation of arbidol treatment, the use of broad-spectrum antibacterial drugs, the use of drugs with unproven anti-coronavirus effects. CONCLUSION: Clinical pharmacists should participate in the optimization of drug treatment programs and provide pharmaceutical care for critically ill COVID-19 patients; this can promote the rational use of drugs. |*Betacoronavirus[MESH] |*Coronavirus Infections[MESH] |*Critical Illness[MESH] |*Pandemics[MESH] |*Pneumonia, Viral[MESH] |COVID-19[MESH] |Drug Evaluation[MESH] |Humans[MESH] |Pharmaceutical Services[MESH]Drug evaluation and pharmaceutical care in a critically ill COVID-19 p(epmc).pdf DeepDyve Pubget Overpricing